Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok

doi:10.1016/s1470-2045(17)30608-3

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Cited By ~ 300

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12351956.13537054 ◽

2011 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70393-x ◽

2012 ◽

Vol 13 (3) ◽

pp. 239-246 ◽

Cited By ~ 3047

Author(s):

Rafael Rosell ◽

Enric Carcereny ◽

Radj Gervais ◽

Alain Vergnenegre ◽

Bartomeu Massuti ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Annals of Oncology ◽

10.1093/annonc/mdv586.02 ◽

2015 ◽

Vol 26 ◽

pp. ix161 ◽

Cited By ~ 10

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8005 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8005-8005 ◽

Cited By ~ 10

Author(s):

Terufumi Kato ◽

Takashi Seto ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Treatment

Download Full-text

TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps8108 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS8108-TPS8108 ◽

Cited By ~ 1

Author(s):

D. Ross Camidge ◽

Juergen Wolf ◽

Jason B. Litten ◽

Linda A Higashi ◽

Jeffrey D. Isaacson ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text